{
    "hands_on_practices": [
        {
            "introduction": "To quantitatively reason about the effects of chemotherapy, we rely on fundamental models of cell death. The log-kill hypothesis provides such a framework, postulating that a given dose of a cytotoxic drug kills a constant *fraction* of cancer cells, not a constant number. This practice problem allows you to apply this principle of first-order kinetics to determine the number of treatment cycles required to reduce a tumor burden to a specific level, illustrating the exponential power of systematic therapy. ",
            "id": "4583518",
            "problem": "An oncologist is modeling the cytotoxic effect of a combination chemotherapy regimen using the log-kill hypothesis, which is grounded in first-order kinetics of cell death: each treatment cycle removes a fixed proportion of malignant cells independent of the absolute tumor burden. A patient presents with an initial tumor burden of $10^{11}$ cells. The planned regimen consistently achieves a $2$-log kill per cycle. Treatment is administered in discrete cycles, and for the purposes of this calculation, assume no regrowth of malignant cells between cycles and that the fractional kill per cycle remains constant throughout therapy.\n\nStarting from the first-order fractional kill framework and the definition of log-kill (where a $k$-log kill reduces the surviving fraction per cycle to $10^{-k}$), derive the inequality that determines the minimum number of cycles $n$ required to reduce the tumor cell count below $10^{3}$ cells. Compute the minimal integer $n$ that satisfies this inequality. Express your final answer as a single integer; no units are required.",
            "solution": "The relevant foundational principle is the first-order kinetics of cytotoxic drug action applied in the log-kill hypothesis. In first-order kill models, each cycle removes a fixed proportion of the existing malignant cells, so the surviving fraction after one cycle is constant and independent of the initial number. The log-kill hypothesis quantifies this by stating that a $k$-log kill leaves a surviving fraction of $10^{-k}$ per cycle.\n\nLet $N_{0}$ denote the initial number of tumor cells and $N_{n}$ the number after $n$ cycles. Under a $k$-log kill per cycle with no regrowth between cycles, the surviving population after $n$ cycles is\n$$\nN_{n} = N_{0} \\times \\left(10^{-k}\\right)^{n} = N_{0} \\times 10^{-k n}.\n$$\nHere, $N_{0} = 10^{11}$ and $k = 2$, so\n$$\nN_{n} = 10^{11} \\times 10^{-2 n} = 10^{11 - 2 n}.\n$$\nWe require the tumor to be reduced below the target threshold $N_{\\text{target}} = 10^{3}$ cells, i.e.,\n$$\nN_{n}  10^{3}.\n$$\nSubstituting $N_{n} = 10^{11 - 2 n}$ yields\n$$\n10^{11 - 2 n}  10^{3}.\n$$\nBecause the base $10$ exponential function is strictly increasing, the inequality of the exponents must hold:\n$$\n11 - 2 n  3.\n$$\nSolving for $n$,\n$$\n11 - 2 n  3 \\;\\;\\Longrightarrow\\;\\; -2 n  -8 \\;\\;\\Longrightarrow\\;\\; 2 n  8 \\;\\;\\Longrightarrow\\;\\; n  4.\n$$\nTherefore, the minimum integer number of cycles that satisfies $n  4$ is\n$$\nn = 5.\n$$\nA quick check confirms this: after $4$ cycles, $N_{4} = 10^{11 - 8} = 10^{3}$, which is not strictly below $10^{3}$. After $5$ cycles, $N_{5} = 10^{11 - 10} = 10^{1} = 10$, which is strictly below $10^{3}$. Thus, the minimal number of cycles is $5$.",
            "answer": "$$\\boxed{5}$$"
        },
        {
            "introduction": "Moving from the theoretical effect of chemotherapy to clinical practice requires a method for determining the appropriate starting dose for an individual patient. For decades, Body Surface Area ($BSA$) has been the standard method for normalizing doses of many cytotoxic agents, providing an empirical surrogate for metabolic rate and drug clearance. This exercise will guide you through the calculation of $BSA$ using the Mosteller formula and the subsequent conversion to an absolute drug dose, a core competency in oncology. ",
            "id": "4583536",
            "problem": "In dose individualization for cytotoxic cancer chemotherapy, many regimens specify the initial cycle dose normalized to Body Surface Area (BSA). Body Surface Area (BSA) is an empirically supported surrogate for physiological scaling that correlates with hepatic and renal clearance for several cytotoxic agents. Consider a regimen specified at $75\\,\\mathrm{mg}/\\mathrm{m}^{2}$. A patient presents with height $170\\,\\mathrm{cm}$ and weight $70\\,\\mathrm{kg}$. Using the clinically standard Mosteller approach, begin from the principle that the BSA estimator is a well-tested, dimensionally consistent function of height and weight that yields area in square meters, and proceed to obtain the appropriate expression to compute BSA from height in centimeters and weight in kilograms. Then evaluate the BSA for this patient and convert the BSA-normalized regimen to an absolute milligram dose.\n\nExpress the final absolute dose in $\\mathrm{mg}$, and round your final answer to four significant figures. Provide any intermediate symbolic steps needed to justify the computation of BSA, but do not assume any unverified shortcuts beyond widely accepted clinical pharmacology facts.",
            "solution": "The task is to compute the absolute dose of a cytotoxic agent for a specific patient. The process involves three main steps: first, to formally present the expression for Body Surface Area (BSA) using the Mosteller method, justifying its structure based on dimensional consistency as requested; second, to calculate the patient's BSA using the provided height and weight; and third, to determine the absolute dose in milligrams.\n\n**Step 1: The Mosteller Formula for Body Surface Area (BSA)**\n\nThe problem statement requires beginning from the principle that the BSA estimator is a dimensionally consistent function of height ($H$) and weight ($W$). Many physiological scaling laws are empirical power-law relationships of the form:\n$$ \\text{BSA} = C \\cdot H^{a} \\cdot W^{b} $$\nwhere $a$ and $b$ are exponents and $C$ is a constant of proportionality. The fundamental dimensions of these quantities are:\n- BSA (Area): $[\\text{BSA}] = L^2$\n- Height (Length): $[H] = L$\n- Weight (treated as Mass): $[W] = M$\n\nThe Mosteller formula is a widely adopted empirical model that uses the specific instance where the exponents are $a = 1/2$ and $b = 1/2$. The functional form is therefore:\n$$ \\text{BSA} = k \\sqrt{H \\cdot W} $$\nFor this equation to be dimensionally consistent, the constant $k$ must carry dimensions to resolve the dimensional difference between the left and right sides. We perform a dimensional analysis:\n$$ [\\text{BSA}] = [k] \\cdot \\sqrt{[H][W]} $$\n$$ L^2 = [k] \\cdot \\sqrt{L \\cdot M} = [k] \\cdot L^{1/2} M^{1/2} $$\nSolving for the dimensions of $k$ yields:\n$$ [k] = \\frac{L^2}{L^{1/2} M^{1/2}} = L^{2 - 1/2} M^{-1/2} = L^{3/2} M^{-1/2} $$\nThis demonstrates that $k$ is not a dimensionless number. Its numerical value is contingent upon the specific units used for BSA, height, and weight.\n\nThe clinically standard Mosteller formula is defined for BSA in square meters ($\\mathrm{m}^2$), height in centimeters ($H_{\\mathrm{cm}}$), and weight in kilograms ($W_{\\mathrm{kg}}$):\n$$ \\text{BSA}_{\\mathrm{m}^2} = \\sqrt{\\frac{H_{\\mathrm{cm}} \\cdot W_{\\mathrm{kg}}}{3600}} $$\nThis expression is structured for practical use and can be rewritten to reveal its constant:\n$$ \\text{BSA}_{\\mathrm{m}^2} = \\frac{1}{\\sqrt{3600}} \\sqrt{H_{\\mathrm{cm}} \\cdot W_{\\mathrm{kg}}} = \\frac{1}{60} \\sqrt{H_{\\mathrm{cm}} \\cdot W_{\\mathrm{kg}}} $$\nHere, the coefficient $\\frac{1}{60}$ is an empirical constant whose value and units ($\\frac{\\mathrm{m}^2}{\\sqrt{\\mathrm{cm} \\cdot \\mathrm{kg}}}$) are tailored for the specified input units.\n\nTo verify the dimensional consistency with a base SI constant, we can convert height to meters ($H_{\\mathrm{m}}$). Knowing that $H_{\\mathrm{cm}} = 100 \\cdot H_{\\mathrm{m}}$, we substitute this into the formula:\n$$ \\text{BSA}_{\\mathrm{m}^2} = \\sqrt{\\frac{(100 \\cdot H_{\\mathrm{m}}) \\cdot W_{\\mathrm{kg}}}{3600}} = \\sqrt{\\frac{100}{3600} H_{\\mathrm{m}} \\cdot W_{\\mathrm{kg}}} = \\sqrt{\\frac{1}{36} H_{\\mathrm{m}} \\cdot W_{\\mathrm{kg}}} $$\n$$ \\text{BSA}_{\\mathrm{m}^2} = \\frac{1}{6} \\sqrt{H_{\\mathrm{m}} \\cdot W_{\\mathrm{kg}}} $$\nIn this form, using only SI base units for length and mass (aside from the derived unit for BSA), the constant is $k_{SI} = 1/6$. For the equation to be dimensionally sound, this constant must possess the derived units of $\\mathrm{m}^{3/2} \\mathrm{kg}^{-1/2}$. The clinical Mosteller formula is thus a dimensionally consistent expression, where the denominator $3600$ conveniently incorporates both the physical scaling factor and the necessary unit conversion factors from $\\mathrm{cm}$ to $\\mathrm{m}$.\n\n**Step 2: Calculation of Patient's BSA**\n\nThe patient's data are:\n- Height $H = 170\\,\\mathrm{cm}$\n- Weight $W = 70\\,\\mathrm{kg}$\n\nWe apply the Mosteller formula obtained in Step 1:\n$$ \\text{BSA} = \\sqrt{\\frac{H \\,[\\mathrm{cm}] \\cdot W \\,[\\mathrm{kg}]}{3600}} $$\n$$ \\text{BSA} = \\sqrt{\\frac{170 \\cdot 70}{3600}} = \\sqrt{\\frac{11900}{3600}} = \\sqrt{\\frac{119}{36}} $$\nThe exact BSA for this patient is:\n$$ \\text{BSA} = \\frac{\\sqrt{119}}{6} \\, \\mathrm{m}^2 $$\n\n**Step 3: Calculation of Absolute Dose**\n\nThe specified regimen gives a normalized dose of $D_{norm} = 75\\,\\mathrm{mg}/\\mathrm{m}^{2}$. The absolute dose, $D_{abs}$, is the product of the normalized dose and the patient's BSA:\n$$ D_{abs} = D_{norm} \\times \\text{BSA} $$\n$$ D_{abs} = \\left(75 \\, \\frac{\\mathrm{mg}}{\\mathrm{m}^2}\\right) \\times \\left(\\frac{\\sqrt{119}}{6} \\, \\mathrm{m}^2\\right) $$\n$$ D_{abs} = \\frac{75 \\sqrt{119}}{6} \\, \\mathrm{mg} $$\nSimplifying the fraction:\n$$ D_{abs} = \\frac{25 \\sqrt{119}}{2} \\, \\mathrm{mg} = 12.5 \\sqrt{119} \\, \\mathrm{mg} $$\n\nTo find the final numerical answer, we evaluate this expression. Using the value of $\\sqrt{119} \\approx 10.908712$:\n$$ D_{abs} \\approx 12.5 \\times 10.908712 \\, \\mathrm{mg} \\approx 136.35890 \\, \\mathrm{mg} $$\nThe problem requires rounding the final answer to four significant figures. The first four significant figures are $1$, $3$, $6$, and $3$. The fifth digit is $5$, which requires rounding up the last significant digit.\n$$ D_{abs} \\approx 136.4 \\, \\mathrm{mg} $$",
            "answer": "$$\n\\boxed{136.4}\n$$"
        },
        {
            "introduction": "While $BSA$-based dosing is a general standard, a more precise, personalized approach can be achieved for certain drugs by targeting a specific systemic drug exposure, measured by the Area Under the plasma Concentration-Time Curve ($AUC$). Carboplatin is the archetypal example of such exposure-targeted dosing, where the Calvert formula leverages a patient's renal function to calculate a dose that achieves a desired $AUC$. This practice demonstrates how fundamental pharmacokinetic principles are translated into a validated, model-based dosing algorithm to optimize the balance of efficacy and toxicity. ",
            "id": "4583530",
            "problem": "An adult patient is planned for carboplatin monotherapy using exposure-targeted dosing. In exposure-targeted dosing for linear pharmacokinetics, the Area Under the plasma Concentration–Time Curve ($AUC$) is related to the administered dose ($Dose$) and the total body clearance ($CL$) by the identity $AUC = \\frac{Dose}{CL}$. For carboplatin, empirical pharmacokinetic characterization supports that total body clearance is well approximated by the sum of the measured Glomerular Filtration Rate ($GFR$) and a fixed nonrenal clearance term of $25\\,\\text{mL/min}$ that reflects nonrenal elimination and non-filtration renal handling in typical adults. Assume the drug is predominantly unbound in plasma such that filtration-limited renal clearance equals $GFR$, and that the pharmacokinetics are linear over the dosing range used. The patient’s measured $GFR$ is $60\\,\\text{mL/min}$, and the target $AUC$ for carboplatin is $5\\,\\text{mg}\\cdot\\text{min}/\\text{mL}$. Using these foundations, derive the required $Dose$ and compute its numerical value. Express the final dose in milligrams and round your answer to three significant figures. Then, concisely articulate, in no more than five sentences, the key modeling assumptions that justify using $CL \\approx GFR + 25\\,\\text{mL/min}$ and targeting $AUC$ for carboplatin dose individualization.",
            "solution": "The problem requires the calculation of the appropriate dose of carboplatin for a patient and an articulation of the underlying modeling assumptions. The relationship between dose, exposure, and clearance for a drug exhibiting linear pharmacokinetics is given by the fundamental identity:\n$$AUC = \\frac{Dose}{CL}$$\nwhere $AUC$ is the Area Under the plasma Concentration-Time Curve, $Dose$ is the total administered dose, and $CL$ is the total body clearance of the drug.\n\nTo calculate the required dose, we can rearrange this equation to solve for $Dose$:\n$$Dose = AUC \\times CL$$\n\nThe problem provides a specific model for carboplatin clearance, known as the Calvert formula, which approximates total body clearance as the sum of the Glomerular Filtration Rate ($GFR$) and a fixed term for nonrenal clearance ($CL_{nr}$):\n$$CL = GFR + CL_{nr}$$\nThe problem states that this nonrenal clearance term is a constant value of $25\\,\\text{mL/min}$. Thus, the formula for total clearance is:\n$$CL = GFR + 25\\,\\text{mL/min}$$\n\nWe are given the following values:\nThe patient's measured Glomerular Filtration Rate, $GFR = 60\\,\\text{mL/min}$.\nThe target Area Under the Curve, $AUC = 5\\,\\text{mg}\\cdot\\text{min}/\\text{mL}$.\n\nFirst, we calculate the patient's total body clearance ($CL$) using the provided model and the patient's $GFR$:\n$$CL = 60\\,\\text{mL/min} + 25\\,\\text{mL/min} = 85\\,\\text{mL/min}$$\n\nNext, we use this calculated clearance and the target $AUC$ to determine the required dose:\n$$Dose = AUC \\times CL$$\n$$Dose = (5\\,\\text{mg}\\cdot\\text{min}/\\text{mL}) \\times (85\\,\\text{mL/min})$$\nThe units of $\\text{mL}$ and $\\text{min}$ cancel out, leaving the dose in units of $\\text{mg}$:\n$$Dose = 5 \\times 85\\,\\text{mg} = 425\\,\\text{mg}$$\nThe problem asks for the answer to be rounded to three significant figures. The calculated value of $425$ already has three significant figures. Therefore, the required dose is $425\\,\\text{mg}$.\n\nThe second part of the task is to articulate the key modeling assumptions that justify this dosing strategy. The use of the formula $CL \\approx GFR + 25\\,\\text{mL/min}$ and the principle of targeting a specific $AUC$ rely on the following foundational assumptions. First, carboplatin must exhibit linear pharmacokinetics, where clearance is constant with respect to drug concentration, thereby establishing a direct proportionality between dose and $AUC$. Second, the patient's measured $GFR$ is assumed to be an accurate and sufficient representation of the drug's renal clearance via glomerular filtration, a premise supported by the fact that carboplatin is poorly protein-bound. Third, all non-renal clearance pathways and any non-filtrational renal handling are presumed to be adequately captured by a single, fixed population constant ($25\\,\\text{mL/min}$) that does not vary significantly. Fourth, the core tenet of this approach is that $AUC$ serves as the most robust surrogate for both the therapeutic efficacy and the dose-limiting toxicities of carboplatin. Lastly, this calculation assumes that the patient's renal function, as measured by $GFR$, remains stable throughout the treatment period.",
            "answer": "$$\\boxed{425}$$"
        }
    ]
}